argenx
ARGX | NASDAQ
$950.95
-$9.09 (-0.95%)
At close: Nov 16, 2026, 4:00 PM ET
$950.95
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
argenx Company Profile
Company profile explainedCompany Profile
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
Key Executives
| Name | Position |
|---|---|
| Karen Massey | Chief Executive Officer & Executive Director |
| Karl Gubitz | Chief Financial Officer |
| Andria Wilk | Global Head of Quality |
| Arjen Lemmen | Vice President of Corporate Development & Strategy |
| Filip Borgions | Chief Technology Innovation Officer |
| Hans de Haard Ir | Co-Founder & Member of Board Advisors |
| Luc Truyen | Chief Medical Officer |
| Malini Moorthy | General Counsel & Corporate Secretary |
| Peter Ulrichts | Chief Scientific Officer |
| Timothy Van Hauwermeiren EMBA | Co-Founder & Non-Independent Non-Executive Chairman of the Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2026 | 6-K | Filing |
| Oct 19, 2026 | 6-K | Filing |
| Oct 08, 2026 | 6-K | Filing |
| Sep 29, 2026 | 6-K | Filing |
| Aug 27, 2026 | 6-K | Filing |
| Aug 27, 2026 | SC TO-T/A | [Amend] Filing |
| Aug 19, 2026 | SC TO-T/A | [Amend] Filing |
| Aug 17, 2026 | 6-K | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2026 | SC TO-T/A | [Amend] Filing |
argenx
| Country | Netherlands |
| IPO Date | May 18, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,863 |
| CEO | Karen Massey |
Contact Details
Laarderhoogtweg 25 Amsterdam,
New Hampshire 1101 EB Netherlands
Stock Details
| Ticker Symbol | ARGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001697862 |
| CUSIP Number | 04016X101 |
| ISIN Number | US04016X1019 |
| SIC Code | 2836 |
Recent News
- 8 days ago / fool.com3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade
- 8 days ago / globenewswire.comUnnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
- 12 days ago / zacks.comBest Biotech Stocks to Buy Now as AI Stocks Tank: ARGX
- 14 days ago / globenewswire.comargenx to Present at Upcoming Investor Conferences
- 25 days ago / fool.comargenx: 3 Key Takeaways for Long-Term Investors
- 26 days ago / seekingalpha.comargenx SE (ARGX) Q3 2026 Earnings Call Transcript
- 26 days ago / marketbeat.comWhat argenex (ARGX) Said on Its Q3 Earnings Call
- 1 month ago / globenewswire.comargenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- 1 month ago / zacks.comargenx Meets Primary Endpoint in Phase II Celiac Disease Study
- 1 month ago / zacks.comARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
Add to Watchlist
Select watchlists to add or remove ARGX